Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Breast Cancer, Tumor, Breast
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
The purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing…
- Conditions
- Breast Cancer, Tumor, Breast, Breast Tumor, Malignant Neoplasm of Breast
- Trial name
- NCT06251544
- Testing
- HTR2 T Cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
HER2-positive Breast Cancer, Male Breast Cancer
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast…
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT02060253
- Testing
- ganetespib, paclitaxel, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymph Node Metastases, Breast Cancer
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer
In the previous study, the investigator established a predictive model for non-sentinel lymph node involvement in early breast cancer (cT1-2cN0, 1-2 SLNs involvement).
- Conditions
- Lymph Node Metastases, Breast Cancer, Predictive Cancer Model
- Trial name
- NCT03280134
- Testing
- axillary lymph node dissection (ALND)
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Four Conversations RCT
The purpose of this study is to see whether patients with metastatic breast cancer, their caregivers, and their healthcare providers can improve in shared decision making (SDM) and preparedness around end of life (EOL) planning…
- Trial name
- NCT02944344
- Testing
- Four Conversations
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Duke University
Non Metastatic Breast Cancer
Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cancer.
The MAEva program combines Acceptance and Committment Therapy (ACT) and mindfulness practices. It is an open and circular intervention, in three sessions (Mindfulness, Acceptance, and Commitment to values).
- Trial name
- MAEva-MCT (NCT07326800)
- Testing
- MAEva program (Meditation, Acceptance and Commitment to Values or "Méditation, Acceptation et Engagements en direction des valeurs"), Discussion group
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Institut de Cancérologie de Lorraine
Advanced Unresectable or Metastatic Breast Cancer
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults.
- Trial name
- NCT06679036
- Testing
- HRS-2189, Fluvustat, HRS-8080
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Triple-negative Breast Cancer
A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
This is an phase II study to prelininarily evaluate the efficacy and safety of JS212 mono therapy or combination therapy in patients with recurrent or metastatic TNBC.
- Trial name
- NCT07876557
- Testing
- JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001
- Where
- 29 sites in China
- Volunteers
- 184 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma Breast Stage IV
Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer
1st-line treatment of HER2/neu overexpressing breast cancer
- Trial name
- NCT00433095
- Testing
- Navelbine, Herceptin, Navelbine (oraly)
- Where
- Germany
- Sponsor
- Ludwig-Maximilians - University of Munich
Invasive Breast Cancer, HER2-positive Breast Cancer
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in…
- Conditions
- Invasive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
- Trial name
- fREEDOM (NCT06328465)
- Testing
- Diffusion whole body MRI
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- European Institute of Oncology
Metastatic Cancer
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant.
- Trial name
- NCT00861107
- Testing
- AlloStim-7, percutaneous tumor cryoablation, AlloStim8 or AlloStim-9
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mirror Biologics, Inc.
Bone Metastases
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone System in the treatment of pain resulting from metastatic bone tumors.
- Trial name
- NCT00981578
- Testing
- ExAblate 2100
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- InSightec
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Breast Cancer, Brain Metastases
Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
Sorafenib is a new type of anti-cancer drug. It belongs to a new class of medications known as tyrosine kinase inhibitors. Sorafenib is thought to work against cancer in many ways. It helps decrease blood supply to the tumor.
- Trial name
- NCT01724606
- Testing
- Whole Brain Radiotherapy (WBRT), Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is…
- Trial name
- HARMONIA (NCT05207709)
- Testing
- Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
- Where
- 71 sites in United States, Portugal and 1 more
- Volunteers
- 61 people
- Sponsor
- SOLTI Breast Cancer Research Group
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
This phase II trial investigates the safety of delivering a part (boost) of radiation treatment before breast surgery in treating patients with breast cancer that has not spread to other places in the body (non-metastatic).
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04871516
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost
- Where
- 11 sites in United States
- Volunteers
- 103 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer Related Lymphedema, Lymphedema, Secondary
Adjustable Compression Wrap Versus Compression Sleeve to Control Breast Cancer-related Lymphedema
This is a randomized clinical trial, in which the use of an Adjustable compression wrap as a compressive therapy to control the upper limb volume of with lymphedema women secondary to breast cancer will be investigated, in…
- Conditions
- Breast Cancer Related Lymphedema, Lymphedema, Secondary, Lymphedema of Upper Arm, Breast Neoplasms
- Trial name
- NCT04881604
- Testing
- Adjustable Compression Wrap, Compression Sleeve
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
HER2-positive Breast Cancer, Recurrent Breast Cancer
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Trial name
- NCT01730833
- Testing
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- City of Hope Medical Center
Breast Neoplasms, Breast Cancer
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor…
- Conditions
- Breast Neoplasms, Breast Cancer, Neoplasm Metastasis
- Trial name
- PROVIDENCE (NCT05573893)
- Where
- 109 sites in Germany
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer.
- Trial name
- NCT01594216
- Testing
- Ruxolitinib, Exemestane
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.